Detalles de la búsqueda
1.
Spliceosome-targeted therapies trigger an antiviral immune response in triple-negative breast cancer.
Cell
; 184(2): 384-403.e21, 2021 01 21.
Artículo
en Inglés
| MEDLINE | ID: mdl-33450205
2.
Temporal trends in COVID-19 outcomes among patients with systemic autoimmune rheumatic diseases: from the first wave through the initial Omicron wave.
Ann Rheum Dis
; 81(12): 1742-1749, 2022 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-35944947
3.
Characteristics associated with poor COVID-19 outcomes in individuals with systemic lupus erythematosus: data from the COVID-19 Global Rheumatology Alliance.
Ann Rheum Dis
; 81(7): 970-978, 2022 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-35172961
4.
Coronavirus disease 2019 outcomes among patients with rheumatic diseases 6 months into the pandemic.
Ann Rheum Dis
; 80(5): 660-666, 2021 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-33257496
5.
Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis: Results from the COVID-19 Global Rheumatology Alliance physician registry.
Ann Rheum Dis
; 80(9): 1137-1146, 2021 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-34049860
6.
The spliceosome is a therapeutic vulnerability in MYC-driven cancer.
Nature
; 525(7569): 384-8, 2015 Sep 17.
Artículo
en Inglés
| MEDLINE | ID: mdl-26331541
7.
Persistence and Evolution of SARS-CoV-2 in an Immunocompromised Host.
N Engl J Med
; 383(23): 2291-2293, 2020 12 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-33176080
8.
Response to: 'Correspondence on 'SARS-CoV-2 antibody response after COVID-19 in patients with rheumatic disease'' by C et al.
Ann Rheum Dis
; 82(6): e131, 2023 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-33692020
9.
Response to: 'COVID-19 in patients with rheumatic diseases: what is the real mortality risk?' by Marques et al.
Ann Rheum Dis
; 81(8): e135, 2022 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-32660976
10.
Clinical characteristics and outcomes of COVID-19 breakthrough infections among vaccinated patients with systemic autoimmune rheumatic diseases.
Ann Rheum Dis
; 81(2): 289-291, 2022 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-34489304
11.
SARS-CoV-2 antibody response after COVID-19 in patients with rheumatic disease.
Ann Rheum Dis
; 80(6): 817-819, 2021 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-33436385
12.
Association Between Race/Ethnicity and COVID-19 Outcomes in Systemic Lupus Erythematosus Patients From the United States: Data From the COVID-19 Global Rheumatology Alliance.
Arthritis Care Res (Hoboken)
; 75(1): 53-60, 2023 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-36239292
13.
Coronavirus Disease 2019 Outcomes Among Recipients of Anti-CD20 Monoclonal Antibodies for Immune-Mediated Diseases: A Comparative Cohort Study.
ACR Open Rheumatol
; 4(3): 238-246, 2022 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-34890478
14.
DMARD disruption, rheumatic disease flare, and prolonged COVID-19 symptom duration after acute COVID-19 among patients with rheumatic disease: A prospective study.
Semin Arthritis Rheum
; 55: 152025, 2022 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-35617780
15.
DMARD disruption, disease flare, and prolonged symptom duration after acute COVID-19 among participants with rheumatic disease: A prospective study.
medRxiv
; 2022 Feb 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-35169813
16.
Development of a Prediction Model for COVID-19 Acute Respiratory Distress Syndrome in Patients With Rheumatic Diseases: Results From the Global Rheumatology Alliance Registry.
ACR Open Rheumatol
; 4(10): 872-882, 2022 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-35869686
17.
Factors associated with severe COVID-19 in people with idiopathic inflammatory myopathy: results from the COVID-19 Global Rheumatology Alliance physician-reported registry.
RMD Open
; 8(2)2022 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-36100295
18.
Environmental and societal factors associated with COVID-19-related death in people with rheumatic disease: an observational study.
Lancet Rheumatol
; 4(9): e603-e613, 2022 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-35909441
19.
COVID-19 Outcomes Among Users of CD20 Inhibitors for Immune-Mediated Diseases: A Comparative Cohort Study.
medRxiv
; 2021 Aug 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-34401883
20.
Laboratory trends, hyperinflammation, and clinical outcomes for patients with a systemic rheumatic disease admitted to hospital for COVID-19: a retrospective, comparative cohort study.
Lancet Rheumatol
; 3(9): e638-e647, 2021 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-34095857